Advice
in the absence of a submission from the holder of the marketing authorisation:
pegylated liposomal irinotecan (Onivyde®) is not recommended for use within NHSScotland.
Indication under review: in combination with oxaliplatin, 5‑fluorouracil (5‑FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.
As a result, we cannot recommend its use within NHSScotland.
Download detailed advice255KB (PDF)
Medicine details
- Medicine name:
- pegylated liposomal irinotecan (Onivyde)
- SMC ID:
- SMC2812
- Indication:
In combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 June 2025